Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Ischemic Heart Disease

Free Subscription Articles published in Am Heart J Retrieve available abstracts of 134 articles: HTML format Text format

Single Articles

December 2018
1. DESCH S, Freund A, Graf T, Fichtlscherer S, et al
   Immediate unselected coronary angiography versus delayed triage in survivors of out-of-hospital cardiac arrest without ST-segment elevation: Design and rationale of the TOMAHAWK trial.
   Am Heart J. 2018;209:20-28.
   PubMed     Text format     Abstract available
   
   
   
2. IBRAHIM NE, McCarthy CP, Shrestha S, Lyass A, et al
   Blood kidney injury molecule-1 predicts short and longer term kidney outcomes in patients undergoing diagnostic coronary and/or peripheral angiography-Results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study.
   Am Heart J. 2018;209:36-46.
   PubMed     Text format     Abstract available
   
   
   
3. FORDYCE CB, Chen AY, Wang TY, Lucas J, et al
   Patterns of use of targeted temperature management for acute myocardial infarction patients following out-of-hospital cardiac arrest: Insights from the National Cardiovascular Data Registry.
   Am Heart J. 2018;206:131-133.
   PubMed     Text format     Abstract available
   
   
   November 2018
4. GIBSON CM, Kerneis M, Yee MK, Daaboul Y, et al
   The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction.
   Am Heart J. 2018;208:81-90.
   PubMed     Text format     Abstract available
   
   
   
5. DOLL JA, Hellkamp AS, Thomas L, Fonarow GC, et al
   The association of pre- and posthospital medication adherence in myocardial infarction patients.
   Am Heart J. 2018;208:74-80.
   PubMed     Text format     Abstract available
   
   
   
6. HEAD T, Henn L, Andreev VP, Herderick EE, et al
   Accelerated coronary atherosclerosis not explained by traditional risk factors in 13% of young individuals.
   Am Heart J. 2018;208:47-54.
   PubMed     Text format     Abstract available
   
   
   
7. PAGIDIPATI NJ, Coles A, Hemal K, Lee KL, et al
   Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease: Insights from the PROMISE trial.
   Am Heart J. 2018;208:28-36.
   PubMed     Text format     Abstract available
   
   
   
8. POLCWIARTEK C, Behrndtz P, Andersen AH, Bregendahl M, et al
   Attitudes and considerations of patients with ST-elevation myocardial infarction toward participation in randomized clinical trials.
   Am Heart J. 2018;208:21-27.
   PubMed     Text format    
   
   
   
9. HELD C, White HD, Stewart RAH, Davies R, et al
   Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.
   Am Heart J. 2018;208:65-73.
   PubMed     Text format     Abstract available
   
   
   
10. TRAN HV, Ash AS, Gore JM, Darling CE, et al
    Twenty-five year trends (1986-2011) in hospital incidence and case-fatality rates of ventricular tachycardia and ventricular fibrillation complicating acute myocardial infarction.
    Am Heart J. 2018;208:1-10.
    PubMed     Text format     Abstract available
    
    
    October 2018
11. LAMBRAKIS K, French JK, Scott IA, Briffa T, et al
    The appropriateness of coronary investigation in myocardial injury and type 2 myocardial infarction (ACT-2): A randomized trial design.
    Am Heart J. 2018;208:11-20.
    PubMed     Text format     Abstract available
    
    
    
12. MUNKHAUGEN J, Ruddox V, Halvorsen S, Dammen T, et al
    BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study.
    Am Heart J. 2018;208:37-46.
    PubMed     Text format     Abstract available
    
    
    
13. MACHLINE-CARRION MJ, Soares RM, Damiani LP, Campos VB, et al
    Rationale and design for a cluster randomized quality-improvement trial to increase the uptake of evidence-based therapies for patients at high cardiovascular risk: The BRIDGE-Cardiovascular Prevention trial.
    Am Heart J. 2018;207:40-48.
    PubMed     Text format     Abstract available
    
    
    
14. PAGIDIPATI NJ, Mudrick DW, Chiswell K, Brucker A, et al
    Sex differences in long-term outcomes of patients across the spectrum of coronary artery disease.
    Am Heart J. 2018;206:51-60.
    PubMed     Text format     Abstract available
    
    
    September 2018
15. PRADHAN AD, Paynter NP, Everett BM, Glynn RJ, et al
    Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.
    Am Heart J. 2018;206:80-93.
    PubMed     Text format     Abstract available
    
    
    
16. GUEDENEY P, Baber U, Claessen B, Aquino M, et al
    Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry.
    Am Heart J. 2018;207:10-18.
    PubMed     Text format     Abstract available
    
    
    
17. HARRISON RW, Radhakrishnan V, Allen JC Jr, Lam PS, et al
    The East-West late lumen loss study: Comparison of angiographic late lumen loss between Eastern and Western drug-eluting stent study cohorts.
    Am Heart J. 2018;206:61-71.
    PubMed     Text format     Abstract available
    
    
    
18. CANNON CP, McGuire DK, Pratley R, Dagogo-Jack S, et al
    Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
    Am Heart J. 2018;206:11-23.
    PubMed     Text format     Abstract available
    
    
    August 2018
19. ELGENDY IY, Mansoor H, Li Q, Guo Y, et al
    Long-term mortality and estimated functional capacity among women with symptoms of ischemic heart disease: From the NHLBI-sponsored Women's Ischemia Syndrome Evaluation.
    Am Heart J. 2018 Aug 30. pii: S0002-8703(18)30252.
    PubMed     Text format     Abstract available
    
    
    
20. LEE J, Nakanishi R, Li D, Shaikh K, et al
    Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis.
    Am Heart J. 2018 Aug 24. pii: S0002-8703(18)30249.
    PubMed     Text format     Abstract available
    
    
    
21. ALFONSO F, Cuesta J, Garcia-Guimaraes M, Gonzalez-Barthol E, et al
    Treatment of patients with restenosis of drug-eluting stents.
    Am Heart J. 2018 Aug 24. pii: S0002-8703(18)30250.
    PubMed     Text format    
    
    
    
22. KANG DY, Wong YTA, Park DW, Park SJ, et al
    The authors reply: Treatment of patients with restenosis of drug-eluting stents.
    Am Heart J. 2018 Aug 23. pii: S0002-8703(18)30251.
    PubMed     Text format    
    
    
    
23. MAURI L, Kirtane AJ, Windecker S, Yeh RW, et al
    Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention.
    Am Heart J. 2018;205:110-117.
    PubMed     Text format     Abstract available
    
    
    
24. EINDHOVEN DC, Wu HW, Kremer SWF, van Erkelens JA, et al
    Mortality differences in acute myocardial infarction patients in the Netherlands: The weekend-effect.
    Am Heart J. 2018;205:70-76.
    PubMed     Text format    
    
    
    
25. CHUNG CJ, Kirtane AJ, Zhang Y, Witzenbichler B, et al
    Impact of high on-aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug-eluting stents.
    Am Heart J. 2018;205:77-86.
    PubMed     Text format     Abstract available
    
    
    
26. LAURSEN PN, Holmvang L, Lonborg J, Kober L, et al
    Comparison between patients included in randomized controlled trials of ischemic heart disease and real-world data. A nationwide study.
    Am Heart J. 2018;204:128-138.
    PubMed     Text format     Abstract available
    
    
    
27. MACK MJ, Abraham WT, Lindenfeld J, Bolling SF, et al
    Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial.
    Am Heart J. 2018;205:1-11.
    PubMed     Text format     Abstract available
    
    
    July 2018
28. BURGESS SN, French JK, Nguyen TL, Leung M, et al
    The impact of incomplete revascularization on early and late outcomes in ST-elevation myocardial infarction.
    Am Heart J. 2018;205:31-41.
    PubMed     Text format     Abstract available
    
    
    
29. PAGIDIPATI NJ, Hellkamp AS, Sharma PP, Wang TY, et al
    High-sensitivity C-reactive protein elevation in patients with prior myocardial infarction in the United States.
    Am Heart J. 2018;204:151-155.
    PubMed     Text format     Abstract available
    
    
    
30. STEVENS ER, Farrell D, Jumkhawala SA, Ladapo JA, et al
    Quality of health economic evaluations for the ACC/AHA stable ischemic heart disease practice guideline: A systematic review.
    Am Heart J. 2018;204:17-33.
    PubMed     Text format     Abstract available
    
    
    
31. GIBBONS RJ, Weintraub WS, Brindis RG
    Moving from volume to value for revascularization in stable ischemic heart disease: A review.
    Am Heart J. 2018 Jul 10. pii: S0002-8703(18)30108.
    PubMed     Text format     Abstract available
    
    
    
32. HUGELSHOFER S, Roffi M, Witassek F, Eberli FR, et al
    Impact of total ischemic time on manual thrombus aspiration benefit during primary percutaneous coronary intervention.
    Am Heart J. 2018;204:34-42.
    PubMed     Text format     Abstract available
    
    
    
33. GNANENTHIRAN SR, Yiannikas J, Lowe HC, Brieger D, et al
    Aspirin hypersensitivity in patients with coronary artery disease: linking pathophysiology to clinical practice.
    Am Heart J. 2018;203:74-81.
    PubMed     Text format     Abstract available
    
    
    
34. RYMER JA, Tempelhof MW, Clare RM, Pieper KS, et al
    Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction.
    Am Heart J. 2018;201:103-110.
    PubMed     Text format     Abstract available
    
    
    
35. VENETSANOS D, Lawesson SS, James S, Koul S, et al
    Bivalirudin versus heparin with primary percutaneous coronary intervention.
    Am Heart J. 2018;201:9-16.
    PubMed     Text format     Abstract available
    
    
    
36. INOHARA T, Pieper K, Wojdyla DM, Patel MR, et al
    Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome.
    Am Heart J. 2018;201:25-32.
    PubMed     Text format     Abstract available
    
    
    June 2018
37. XU H, Faxen J, Szummer K, Trevisan M, et al
    Dyskalemias and adverse events associated with discharge potassium in acute myocardial infarction.
    Am Heart J. 2018;205:53-62.
    PubMed     Text format     Abstract available
    
    
    
38. CHI G, Kerneis M, Kalayci A, Liu Y, et al
    Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial.
    Am Heart J. 2018;203:17-24.
    PubMed     Text format     Abstract available
    
    
    
39. PAOLI G, Notarangelo MF, Mattioli M, La Sala R, et al
    ALLiance for sEcondary PREvention after an acute coronary syndrome. The ALLEPRE trial: A multicenter fully nurse-coordinated intensive intervention program.
    Am Heart J. 2018;203:12-16.
    PubMed     Text format    
    
    
    
40. GREEN JB, Hernandez AF, D'Agostino RB, Granger CB, et al
    Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics.
    Am Heart J. 2018;203:30-38.
    PubMed     Text format     Abstract available
    
    
    
41. ATZEMA CL, Dorian P, Fang J, Tu JV, et al
    A clinical decision instrument to predict 30-day death and cardiovascular hospitalizations after an emergency department visit for atrial fibrillation: The Atrial Fibrillation in the Emergency Room, Part 2 (AFTER2) study.
    Am Heart J. 2018;203:85-92.
    PubMed     Text format     Abstract available
    
    
    
42. HJORT M, Lindahl B, Baron T, Jernberg T, et al
    Prognosis in relation to high-sensitivity cardiac troponin T levels in patients with myocardial infarction and non-obstructive coronary arteries.
    Am Heart J. 2018;200:60-66.
    PubMed     Text format     Abstract available
    
    
    
43. ISRAR MZ, Heaney LM, Ng LL, Suzuki T, et al
    B-type natriuretic peptide molecular forms for risk stratification and prediction of outcome after acute myocardial infarction.
    Am Heart J. 2018;200:37-43.
    PubMed     Text format     Abstract available
    
    
    
44. CAPLICE NM, DeVoe MC, Choi J, Dahly D, et al
    Randomized placebo controlled trial evaluating the safety and efficacy of single low-dose intracoronary insulin-like growth factor following percutaneous coronary intervention in acute myocardial infarction (RESUS-AMI).
    Am Heart J. 2018;200:110-117.
    PubMed     Text format     Abstract available
    
    
    
45. CARSON JL, Stanworth SJ, Alexander JH, Roubinian N, et al
    Clinical trials evaluating red blood cell transfusion thresholds: An updated systematic review and with additional focus on patients with cardiovascular disease.
    Am Heart J. 2018;200:96-101.
    PubMed     Text format     Abstract available
    
    
    
46. ELFWEN L, Lagedal R, James S, Jonsson M, et al
    Coronary angiography in out-of-hospital cardiac arrest without ST elevation on ECG-Short- and long-term survival.
    Am Heart J. 2018;200:90-95.
    PubMed     Text format     Abstract available
    
    
    
47. WIVIOTT SD, Raz I, Bonaca MP, Mosenzon O, et al
    The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
    Am Heart J. 2018;200:83-89.
    PubMed     Text format     Abstract available
    
    
    
48. LATTUCA B, Barber-Chamoux N, Alos B, Sfaxi A, et al
    Impact of video on the understanding and satisfaction of patients receiving informed consent before elective inpatient coronary angiography: A randomized trial.
    Am Heart J. 2018;200:67-74.
    PubMed     Text format     Abstract available
    
    
    
49. PASTORI D, Pignatelli P, Cribari F, Carnevale R, et al
    Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naive patients with atrial fibrillation.
    Am Heart J. 2018;200:32-36.
    PubMed     Text format     Abstract available
    
    
    
50. LOPES RD, Vora AN, Liaw D, Granger CB, et al
    An open-Label, 2 x 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention:
    Am Heart J. 2018;200:17-23.
    PubMed     Text format     Abstract available
    
    
    May 2018
51. ITSIOPOULOS C, Kucianski T, Mayr HL, van Gaal WJ, et al
    The AUStralian MEDiterranean Diet Heart Trial (AUSMED Heart Trial): A randomized clinical trial in secondary prevention of coronary heart disease in a multiethnic Australian population: Study protocol.
    Am Heart J. 2018;203:4-11.
    PubMed     Text format     Abstract available
    
    
    
52. VARDENY O, Udell JA, Joseph J, Farkouh ME, et al
    High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial.
    Am Heart J. 2018;202:97-103.
    PubMed     Text format     Abstract available
    
    
    
53. HOLMEN J, Herlitz J, Axelsson C
    Immediate coronary intervention in prehospital cardiac arrest-Aiming to save lives.
    Am Heart J. 2018 May 22. pii: S0002-8703(18)30158.
    PubMed     Text format    
    
    
    
54. LI S, Blumenthal JA, Shi C, Millican D, et al
    I-CARE randomized clinical trial integrating depression and acute coronary syndrome care in low-resource hospitals in China: Design and rationale.
    Am Heart J. 2018;202:109-115.
    PubMed     Text format     Abstract available
    
    
    
55. JAKOBSEN L, Christiansen EH, Maeng M, Kristensen SD, et al
    Randomized clinical comparison of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent with the sirolimus-eluting Orsiro stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian
    Am Heart J. 2018;202:49-53.
    PubMed     Text format     Abstract available
    
    
    
56. HSU S, Kambhampati S, Sciortino CM, Russell SD, et al
    Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock.
    Am Heart J. 2018;199:181-191.
    PubMed     Text format     Abstract available
    
    
    
57. WANG A, Wu A, Wojdyla D, Lopes RD, et al
    Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery.
    Am Heart J. 2018;199:150-155.
    PubMed     Text format     Abstract available
    
    
    
58. GIANOS E, Schoenthaler A, Guo Y, Zhong J, et al
    Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trial.
    Am Heart J. 2018;199:37-43.
    PubMed     Text format     Abstract available
    
    
    
59. BRINKLEY DM JR, Ho KKL, Drazner MH, Kociol RD, et al
    The prognostic value of the relationship between right atrial and pulmonary capillary wedge pressure in diverse cardiovascular conditions.
    Am Heart J. 2018;199:31-36.
    PubMed     Text format     Abstract available
    
    
    
60. MARWICK TH, Whitmore K, Nicholls SJ, Stanton T, et al
    Rationale and design of a trial to personalize risk assessment in familial coronary artery disease.
    Am Heart J. 2018;199:22-30.
    PubMed     Text format     Abstract available
    
    
    
61. THEODORAKIS MJ, Coleman RL, Feng H, Chan J, et al
    Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants.
    Am Heart J. 2018;199:170-175.
    PubMed     Text format    
    
    
    
62. LACHMAN S, Terbraak MS, Limpens J, Jorstad H, et al
    The prognostic value of heart rate recovery in patients with coronary artery disease: A systematic review and meta-analysis.
    Am Heart J. 2018;199:163-169.
    PubMed     Text format     Abstract available
    
    
    
63. GHARACHOLOU SM, Ijioma NN, Lennon RJ, Rihal CS, et al
    Characteristics and long term outcomes of patients with acute coronary syndromes due to culprit left main coronary artery disease treated with percutaneous coronary intervention.
    Am Heart J. 2018;199:156-162.
    PubMed     Text format     Abstract available
    
    
    
64. YAO X, Gersh BJ, Sangaralingham LR, Shah ND, et al
    Risk of cardiovascular events and incident atrial fibrillation in patients without prior atrial fibrillation: Implications for expanding the indications for anticoagulation.
    Am Heart J. 2018;199:137-143.
    PubMed     Text format     Abstract available
    
    
    
65. BOSWORTH HB, Olsen MK, McCant F, Stechuchak KM, et al
    Telemedicine cardiovascular risk reduction in veterans: The CITIES trial.
    Am Heart J. 2018;199:122-129.
    PubMed     Text format     Abstract available
    
    
    April 2018
66. PATEL KK, Arnold SV, Chan PS, Tang Y, et al
    Validation of the Seattle angina questionnaire in women with ischemic heart disease.
    Am Heart J. 2018;201:117-123.
    PubMed     Text format     Abstract available
    
    
    
67. SPRUILL TM, Reynolds HR, Dickson VV, Shallcross AJ, et al
    Telephone-based mindfulness training to reduce stress in women with myocardial infarction: Rationale and design of a multicenter randomized controlled trial.
    Am Heart J. 2018;202:61-67.
    PubMed     Text format     Abstract available
    
    
    
68. O'NEILL WW, Grines C, Schreiber T, Moses J, et al
    Analysis of outcomes for 15,259 US patients with acute myocardial infarction cardiogenic shock (AMICS) supported with the Impella device.
    Am Heart J. 2018;202:33-38.
    PubMed     Text format     Abstract available
    
    
    
69. PENNY WF, Henry TD, Watkins MW, Patel AN, et al
    Design of a Phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction: The FLOURISH Clinical Trial.
    Am Heart J. 2018;201:111-116.
    PubMed     Text format     Abstract available
    
    
    
70. MUHLESTEIN JB, May HT, Galenko O, Knowlton KU, et al
    GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography: The intermountain heart collaborative study.
    Am Heart J. 2018;202:27-32.
    PubMed     Text format     Abstract available
    
    
    
71. RAVAL AN, Cook TD, Duckers HJ, Johnston PV, et al
    The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: Trial rationale and study d
    Am Heart J. 2018;201:141-148.
    PubMed     Text format     Abstract available
    
    
    
72. FORD TJ, Corcoran D, Oldroyd KG, McEntegart M, et al
    Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial.
    Am Heart J. 2018;201:86-94.
    PubMed     Text format     Abstract available
    
    
    
73. RYMER JA, Kaltenbach LA, Anstrom KJ, Fonarow GC, et al
    Hospital evaluation of health literacy and associated outcomes in patients after acute myocardial infarction.
    Am Heart J. 2018;198:97-107.
    PubMed     Text format     Abstract available
    
    
    
74. CHEW DS, Wilton SB, Kavanagh K, Southern DA, et al
    Left ventricular ejection fraction reassessment post-myocardial infarction: Current clinical practice and determinants of adverse remodeling.
    Am Heart J. 2018;198:91-96.
    PubMed     Text format     Abstract available
    
    
    
75. KINNAIRD T, Cockburn J, Gallagher S, Choudhury A, et al
    Temporal changes in radial access use, associates and outcomes in patients undergoing PCI using rotational atherectomy between 2007 and 2014: results from the British Cardiovascular Intervention Society national database.
    Am Heart J. 2018;198:46-54.
    PubMed     Text format     Abstract available
    
    
    
76. CACOUB P, Nahon P, Layese R, Blaise L, et al
    Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients.
    Am Heart J. 2018;198:4-17.
    PubMed     Text format     Abstract available
    
    
    
77. BISHAWI M, Hattler B, Almassi GH, Spertus JA, et al
    Preoperative factors associated with worsening in health-related quality of life following coronary artery bypass grafting in the Randomized On/Off Bypass (ROOBY) trial.
    Am Heart J. 2018;198:33-38.
    PubMed     Text format     Abstract available
    
    
    
78. AL RIFAI M, Greenland P, Blaha MJ, Michos ED, et al
    Factors of health in the protection against death and cardiovascular disease among adults with subclinical atherosclerosis.
    Am Heart J. 2018;198:180-188.
    PubMed     Text format     Abstract available
    
    
    
79. NAVAR AM, Pencina MJ, Mulder H, Elias P, et al
    Improving patient risk communication: Translating cardiovascular risk into standardized risk percentiles.
    Am Heart J. 2018;198:18-24.
    PubMed     Text format     Abstract available
    
    
    
80. TOMASELLI G, Roach WH, Pina IL, Oster ME, et al
    Government continues to have an important role in promoting cardiovascular health.
    Am Heart J. 2018;198:160-165.
    PubMed     Text format    
    
    
    
81. BOWMAN L, Mafham M, Stevens W, Haynes R, et al
    ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes.
    Am Heart J. 2018;198:135-144.
    PubMed     Text format     Abstract available
    
    
    March 2018
82. BOHULA EA, Scirica BM, Fanola C, Inzucchi SE, et al
    Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.
    Am Heart J. 2018;202:39-48.
    PubMed     Text format     Abstract available
    
    
    
83. BERWANGER O, Nicolau JC, Carvalho AC, Jiang L, et al
    Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial.
    Am Heart J. 2018;202:89-96.
    PubMed     Text format     Abstract available
    
    
    
84. LOOP MS, McClure LA, Levitan EB, Al-Hamdan MZ, et al
    Fine particulate matter and incident coronary heart disease in the REGARDS cohort.
    Am Heart J. 2018;197:94-102.
    PubMed     Text format     Abstract available
    
    
    
85. SHAVADIA JS, French W, Hellkamp AS, Thomas L, et al
    Comprehensive electrocardiogram-to-device time for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: A report from the American Heart Association mission: Lifeline program.
    Am Heart J. 2018;197:9-17.
    PubMed     Text format     Abstract available
    
    
    
86. HAYS AG, Iantorno M, Schar M, Lai S, et al
    The influence of febuxostat on coronary artery endothelial dysfunction in patients with coronary artery disease: A phase 4 randomized, placebo-controlled, double-blind, crossover trial.
    Am Heart J. 2018;197:85-93.
    PubMed     Text format     Abstract available
    
    
    
87. SONG YB, Oh SK, Oh JH, Im ES, et al
    Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial.
    Am Heart J. 2018;197:77-84.
    PubMed     Text format     Abstract available
    
    
    
88. EGGERS KM, Jernberg T, Lindahl B
    High-sensitivity cardiac troponin T, left ventricular function, and outcome in non-ST elevation acute coronary syndrome.
    Am Heart J. 2018;197:70-76.
    PubMed     Text format     Abstract available
    
    
    
89. LAGEDAL R, Elfwen L, James S, Oldgren J, et al
    Design of DISCO-Direct or Subacute Coronary Angiography in Out-of-Hospital Cardiac Arrest study.
    Am Heart J. 2018;197:53-61.
    PubMed     Text format     Abstract available
    
    
    
90. WONG YTA, Kang DY, Lee JB, Rha SW, et al
    Comparison of drug-eluting stents and drug-coated balloon for the treatment of drug-eluting coronary stent restenosis: A randomized RESTORE trial.
    Am Heart J. 2018;197:35-42.
    PubMed     Text format     Abstract available
    
    
    
91. REDFORS B, Genereux P, Witzenbichler B, Maehara A, et al
    Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study.
    Am Heart J. 2018;197:142-149.
    PubMed     Text format     Abstract available
    
    
    
92. KOPIN D, Jones WS, Sherwood MW, Wojdyla DM, et al
    Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
    Am Heart J. 2018;197:133-141.
    PubMed     Text format     Abstract available
    
    
    
93. HWANG D, Park KW, Lee JM, Rhee TM, et al
    Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease.
    Am Heart J. 2018;197:103-112.
    PubMed     Text format     Abstract available
    
    
    
94. SHERWOOD MW, Lopes RD, Sun JL, Liaw D, et al
    Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial.
    Am Heart J. 2018;197:1-8.
    PubMed     Text format     Abstract available
    
    
    February 2018
95. LENG WX, Yang J, Li W, Wang Y, et al
    Rationale and design of the DEAR-OLD trial: Randomized evaluation of routinely Deferred versus EARly invasive strategy in elderly patients of 75 years or OLDer with non-ST-elevation myocardial infarction.
    Am Heart J. 2018;196:65-73.
    PubMed     Text format     Abstract available
    
    
    
96. BAGAI A, Goodman SG, Cantor WJ, Vicaut E, et al
    Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study.
    Am Heart J. 2018;196:56-64.
    PubMed     Text format     Abstract available
    
    
    
97. GUIMARAES PO, Leonardi S, Huang Z, Wallentin L, et al
    Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
    Am Heart J. 2018;196:28-35.
    PubMed     Text format     Abstract available
    
    
    
98. KILIC S, Fabris E, Van't Hof AWJ, Hamm CW, et al
    Thrombus aspiration and prehospital ticagrelor administration in ST-elevation myocardial infarction: Findings from the ATLANTIC trial.
    Am Heart J. 2018;196:1-8.
    PubMed     Text format     Abstract available
    
    
    
99. DUPRE ME, Xu H, Granger BB, Lynch SM, et al
    Access to routine care and risks for 30-day readmission in patients with cardiovascular disease.
    Am Heart J. 2018;196:9-17.
    PubMed     Text format     Abstract available
    
    
    
100. MCCARTHY CP, McEvoy JW, Januzzi JL Jr.
     Biomarkers in stable coronary artery disease.
     Am Heart J. 2018;196:82-96.
     PubMed     Text format     Abstract available
     
     
     
101. ANYANWAGU U, Mamza J, Donnelly R, Idris I, et al
     Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study.
     Am Heart J. 2018;196:18-27.
     PubMed     Text format     Abstract available
     
     
     
102. KHAZANIE P, Al-Khatib SM, Wang TY, Crowley MJ, et al
     Training cardiovascular outcomes researchers: A survey of mentees and mentors to identify critical training gaps and needs.
     Am Heart J. 2018;196:170-177.
     PubMed     Text format     Abstract available
     
     
     
103. CROWLEY MJ, Al-Khatib SM, Wang TY, Khazanie P, et al
     How well does early-career investigators' cardiovascular outcomes research training align with funded outcomes research?
     Am Heart J. 2018;196:163-169.
     PubMed     Text format     Abstract available
     
     
     
104. VRANCKX P, Lewalter T, Valgimigli M, Tijssen JG, et al
     Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial
     Am Heart J. 2018;196:105-112.
     PubMed     Text format     Abstract available
     
     
     January 2018
105. AFANA M, Gurm HS, Seth M, Frazier KM, et al
     Primary percutaneous coronary intervention at centers with and without on-site surgical support: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
     Am Heart J. 2018;195:99-107.
     PubMed     Text format     Abstract available
     
     
     
106. TARANTINI G, Ueshima D, D'Amico G, Masiero G, et al
     Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: A systematic review and meta-analysis.
     Am Heart J. 2018;195:78-85.
     PubMed     Text format     Abstract available
     
     
     
107. ISSA OM, Roberts R, Mark DB, Boineau R, et al
     Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT).
     Am Heart J. 2018;195:70-77.
     PubMed     Text format     Abstract available
     
     
     
108. BOSSARD M, Binbraik Y, Beygui F, Pitt B, et al
     Mineralocorticoid receptor antagonists in patients with acute myocardial infarction - A systematic review and meta-analysis of randomized trials.
     Am Heart J. 2018;195:60-69.
     PubMed     Text format     Abstract available
     
     
     
109. LIU E, Hsueh L, Kim H, Vidovich MI, et al
     Global geographical variation in patient characteristics in percutaneous coronary intervention clinical trials: A systematic review and meta-analysis.
     Am Heart J. 2018;195:39-49.
     PubMed     Text format     Abstract available
     
     
     
110. HESS PL, Kennedy K, Cowherd M, Virani SS, et al
     Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project.
     Am Heart J. 2018;195:151-152.
     PubMed     Text format    
     
     
     
111. VEMULAPALLI S, Holmes DR Jr, Dai D, Matsouaka R, et al
     Valve hemodynamic deterioration and cardiovascular outcomes in TAVR: A report from the STS/ACC TVT Registry.
     Am Heart J. 2018;195:1-13.
     PubMed     Text format     Abstract available
     
     
     December 2017
112. ILIESCU CA, Cilingiroglu M, Giza DE, Rosales O, et al
     "Bringing on the light" in a complex clinical scenario: Optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry).
     Am Heart J. 2017;194:83-91.
     PubMed     Text format     Abstract available
     
     
     
113. QADERDAN K, Vos GA, McAndrew T, Steg PG, et al
     Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials.
     Am Heart J. 2017;194:73-82.
     PubMed     Text format     Abstract available
     
     
     
114. INOHARA T, Numasawa Y, Higashi T, Ueda I, et al
     Predictors of high cost after percutaneous coronary intervention: A review from Japanese multicenter registry overviewing the influence of procedural complications.
     Am Heart J. 2017;194:61-72.
     PubMed     Text format     Abstract available
     
     
     
115. DESAI NR, Kennedy KF, Cohen DJ, Connolly T, et al
     Contemporary risk model for inhospital major bleeding for patients with acute myocardial infarction: The acute coronary treatment and intervention outcomes network (ACTION) registry(R)-Get With The Guidelines (GWTG)(R).
     Am Heart J. 2017;194:16-24.
     PubMed     Text format     Abstract available
     
     
     
116. HIRJI SA, Stevens SR, Shaw LK, Campbell EC, et al
     Predicting risk of cardiac events among ST-segment elevation myocardial infarction patients with conservatively managed non-infarct-related artery coronary artery disease: An analysis of the Duke Databank for Cardiovascular Disease.
     Am Heart J. 2017;194:116-124.
     PubMed     Text format     Abstract available
     
     
     
117. GO AS, Fan D, Sung SH, Inveiss AI, et al
     Contemporary rates and correlates of statin use and adherence in nondiabetic adults with cardiovascular risk factors: The KP CHAMP study.
     Am Heart J. 2017;194:25-38.
     PubMed     Text format     Abstract available
     
     
     November 2017
118. MUSTO C, De Felice F, Rigattieri S, Chin D, et al
     Instantaneous wave-free ratio and fractional flow reserve for the assessment of nonculprit lesions during the index procedure in patients with ST-segment elevation myocardial infarction: The WAVE study.
     Am Heart J. 2017;193:63-69.
     PubMed     Text format     Abstract available
     
     
     
119. RUSSO JJ, Goodman SG, Cantor WJ, Ko DT, et al
     Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis.
     Am Heart J. 2017;193:46-54.
     PubMed     Text format     Abstract available
     
     
     
120. AKINTOYE E, Briasoulis A, Afonso L
     Biochemical risk markers and 10-year incidence of atherosclerotic cardiovascular disease: independent predictors, improvement in pooled cohort equation, and risk reclassification.
     Am Heart J. 2017;193:95-103.
     PubMed     Text format     Abstract available
     
     
     
121. LEE PH, Lee JY, Lee CW, Han S, et al
     Long-term outcomes of bypass grafting versus drug-eluting stenting for left main coronary artery disease: Results from the IRIS-MAIN registry.
     Am Heart J. 2017;193:76-83.
     PubMed     Text format     Abstract available
     
     
     
122. DOROS G, Massaro JM, Kandzari DE, Waksman R, et al
     Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach.
     Am Heart J. 2017;193:35-45.
     PubMed     Text format     Abstract available
     
     
     
123. CHIANG MH, Wu HH, Shih CJ, Chen YT, et al
     Association between influenza vaccination and reduced risks of major adverse cardiovascular events in elderly patients.
     Am Heart J. 2017;193:1-7.
     PubMed     Text format     Abstract available
     
     
     
124. SHADDY R, Canter C, Halnon N, Kochilas L, et al
     Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study).
     Am Heart J. 2017;193:23-34.
     PubMed     Text format     Abstract available
     
     
     October 2017
125. WAKSMAN R, Torguson R, Spad MA, Garcia-Garcia H, et al
     The Lipid-Rich Plaque Study of vulnerable plaques and vulnerable patients: Study design and rationale.
     Am Heart J. 2017;192:98-104.
     PubMed     Text format     Abstract available
     
     
     
126. JESSEE R, Peart E, Beineke P, Rosenberg S, et al
     Rheumatoid arthritis complicates noninvasive whole blood gene expression testing for coronary artery disease.
     Am Heart J. 2017;192:13-18.
     PubMed     Text format     Abstract available
     
     
     
127. DEHGHANI P, Lavoie A, Lavi S, Crawford JJ, et al
     Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.
     Am Heart J. 2017;192:105-112.
     PubMed     Text format     Abstract available
     
     
     
128. ALBERT MA, Durazo EM, Slopen N, Zaslavsky AM, et al
     Cumulative psychological stress and cardiovascular disease risk in middle aged and older women: Rationale, design, and baseline characteristics.
     Am Heart J. 2017;192:1-12.
     PubMed     Text format     Abstract available
     
     
     September 2017
129. WALLERT J, Held C, Madison G, Olsson EM, et al
     Temporal changes in myocardial infarction incidence rates are associated with periods of perceived psychosocial stress: A SWEDEHEART national registry study.
     Am Heart J. 2017;191:12-20.
     PubMed     Text format     Abstract available
     
     
     
130. GUDNADOTTIR GS, Andersen K, Thrainsdottir IS, James SK, et al
     Gender differences in coronary angiography, subsequent interventions, and outcomes among patients with acute coronary syndromes.
     Am Heart J. 2017;191:65-74.
     PubMed     Text format     Abstract available
     
     
     
131. FARB A, Zuckerman BD
     Clinical event adjudication in cardiovascular device trials: An Food and Drug Administration perspective.
     Am Heart J. 2017;191:62-64.
     PubMed     Text format    
     
     
     
132. REN HY, Khera A, de Lemos JA, Ayers CR, et al
     Soluble endothelial cell-selective adhesion molecule and incident cardiovascular events in a multiethnic population.
     Am Heart J. 2017;191:55-61.
     PubMed     Text format     Abstract available
     
     
     
133. KIM Y, Soffler M, Paradise S, Jelani QU, et al
     Depression is associated with recurrent chest pain with or without coronary artery disease: A prospective cohort study in the emergency department.
     Am Heart J. 2017;191:47-54.
     PubMed     Text format     Abstract available
     
     
     
134. WEI J, Mehta PK, Grey E, Garberich RF, et al
     Sex-based differences in quality of care and outcomes in a health system using a standardized STEMI protocol.
     Am Heart J. 2017;191:30-36.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: